Aggressive B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Aggressive B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
This Phase 3 clinical trial (NCT06230224) compares odronextamab to standard of care in adults with previously treated aggressive B-cell non-…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating CRS profile optimization for glofitamab combined with gemcitabine and oxaliplatin in relapsed/refra…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study evaluating SYS6055 Injection in participants with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. The trial is c…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase I/II clinical trial evaluating EMB-07 in combination therapy for aggressive B-cell non-Hodgkin lymphoma; currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy [Phase 2]
A Phase 2 clinical trial investigates golcadomide in combination with rituximab as bridging therapy for relapsed or refractory aggressive B-…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
This clinical trial update describes a study using DNA sequencing to monitor minimal residual disease in aggressive B-cell non-Hodgkin lymph…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) [Phase 2]
A Phase 2 clinical trial (JASPIS-01) evaluating MEN1703 (SEL24) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma is current…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL [NA]
A clinical trial is recruiting for an integrated radiotherapy-optimized ASCT sequential CAR-T therapy for relapsed or refractory aggressive …
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trials are evaluating CAR-T cell therapy for relapsed or refractory malignant hematologic tumors, including aggressi…
-
CLINICAL_TRIALS research · 2014-07-08Clinical Trial Update: Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas [Phase 2]
This clinical trial update describes a Phase 2 study evaluating thiotepa, busulfan, and fludarabine in patients with refractory or early-rel…